Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer

Nishi, Masaaki; Shimada, Mistuo; Tokunaga, Takuya; Higashijima, Jun; Yoshikawa, Kozo; Kashihara, Hideya; Takasu, Chie; Ishikawa, Daichi; Wada, Yuma; Eto, Shohei; Yoshimoto, Toshiaki

doi:10.1186/s12957-021-02319-x

Cited by 17 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 LCR could be an important predictive biomarker for the prognosis of patients with lower rectal cancer who undergo chemoradiotherapy followed by curative surgery. 19 Fan and Z et al showed that pretreatment of the C-reactive proteinlymphocyte ratio could be considered a feasible biomarker for the prognostic prediction of PC. 20 Tumor-infiltrating lymphocytes (TILs) are critical markers of the anti-tumor immune response, and positive associations have been described between the abundance of TILs and the favorable of patients with various cancers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Impact of Lymphocyte-to-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Pancreatic Cancer

Iseda

Iguchi

Hirose

et al. 2022

The American Surgeon™

View full text Add to dashboard Cite

Background Increasing evidence indicates that increased systemic inflammation is correlated with poorer cancer-specific survival in various cancer types. This study aimed to evaluate the prognostic value of various combinations of inflammatory factors in patients who underwent surgical resection for pancreatic cancer (PC). Methods We retrospectively analyzed 97 consecutive patients with PC who underwent pancreatectomy. We assessed the predictive impact for recurrence using a combination of 5 inflammatory markers and focused on the lymphocyte-C-reactive protein ratio (LCR) to elucidate its prognostic and predictive value for recurrence-free survival (RFS) and overall survival (OS) in univariate and multivariate analyses using the Cox proportional hazards model. Results Low preoperative LCR was correlated with low serum hemoglobin, low serum albumin concentration, high frequency of microscopic vascular invasion, and high frequency of microscopic perineural invasion. The low LCR group had significantly worse RFS and OS. Lower preoperative LCR was an independent predictor of shorter RFS and OS in this cohort. Discussion Preoperative LCR is a novel and convenient prognostic marker for patients with PC. Patients with low LCR may require more favorable intensive therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…18 LCR could be an important predictive biomarker for the prognosis of patients with lower rectal cancer who undergo chemo-radiotherapy followed by curative surgery. 19 Fan and Z et al showed that pretreatment of the C-reactive protein-lymphocyte ratio could be considered a feasible biomarker for the prognostic prediction of PC. 20…”

Section: Discussionmentioning

confidence: 99%

Prognostic Impact of Lymphocyte-to-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Pancreatic Cancer

Iseda

Iguchi

Hirose

et al. 2022

The American Surgeon™

View full text Add to dashboard Cite

show abstract

“…The authors identified an elevated pretreatment CRP level as a significant prognostic factor for poor OS and DFS, in line with our results. Recently, the low levels of the lymphocyte-CRP ratio found in rectal cancer patients before nCRT were considered an independent prognostic factor for both recurrence-free survival and OS [57,58].…”

Section: Discussionmentioning

confidence: 99%

C-Reactive Protein as Predictive Biomarker for Response to Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Retrospective Study

Aires

Rodrigues

Piñeiro‐Lamas

et al. 2022

Cancers

View full text Add to dashboard Cite

The standard of care for the treatment of locally advanced rectal cancer is neoadjuvant chemoradiotherapy (nCRT) followed by surgery, but complete response rates are reduced. To find predictive biomarkers of response to therapy, we conducted a retrospective study evaluating blood biomarkers before nCRT. Hemoglobin (Hg), C-reactive protein (CRP), platelets, carcinoembryonic antigen, carbohydrate antigen 19.9 levels, and neutrophil/lymphocyte ratio were obtained from 171 rectal cancer patients before nCRT. Patients were classified as responders (Ryan 0–1; ycT0N0), 59.6% (n = 102), or nonresponders (Ryan 2–3), 40.3% (n = 69), in accordance with the Ryan classification. A logistic regression using prognostic pretreatment factors identified CRP ≤ 3.5 (OR = 0.05; 95%CI: 0.01–0.21) as a strong independent predictor of response to treatment. Multivariate analysis showed that CRP was an independent predictor of disease-free survival (DFS) (HR = 5.48; 95%CI: 1.54–19.48) and overall survival (HR = 6.10; 95%CI 1.27–29.33) in patients treated with nCRT. Platelets were an independent predictor of DFS (HR = 3.068; 95%CI: 1.29–7.30) and OS (HR= 4.65; 95%CI: 1.66–13.05) and Hg was revealed to be an independent predictor of DFS (HR = 0.37; 95%CI: 0.15–0.90) in rectal cancer patients treated with nCRT. The lower expression of CRP is independently associated with an improved response to nCRT, DFS, and OS.

show abstract

“…Increasing studies have found that high LCR predicts a good prognosis in different tumors [15,16,17,18]. However, some other studies have a different opinion [19,20,21]. Whether LCR is a reliable prognostic in ammatory immune marker remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of lymphocyte-to-C-reactive-protein ratio in cancers

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Systemic inflammation and immune nutritional status affect tumor progression and patient survival. Lymphocyte-to-C-reactive-protein ratio(LCR) as inflammatory immune index has been reported to be associated with prognosis of various cancers. However, the results are controversial. Therefore, the aim of this study was to comprehensively evaluate the clinical value of LCR in cancers through a meta-analysis. Methods A comprehensive search of relevant studies was performed by scrutinizing the databases until March 31, 2023. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate overall survival (OS), disease-free survival (DFS), recurrence free survival (RFS), progression-free survival (PFS) and cancer-specific survival (CSS). Results A total of 31 studies from 29 articles involving 11429 patients were included in the study. The pooled analysis showed that patients with high LCR was significantly associated with favorable OS (HR: 0.51,95% CI:0.48–0.55),DFS (HR: 0.55,95% CI:0.43–0.70),RFS (HR:0.57,95% CI:0.48–0.67),PFS (HR: 0.50,95% CI:0.27–0.92) and CSS (HR:0.53,95% CI:0.42–0.67).Sensitivity analysis confirmed the reliability of these results. Conclusions LCR can be used as an effective prognostic marker in cancers.

show abstract

Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer

Cited by 17 publications

References 36 publications

Prognostic Impact of Lymphocyte-to-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Pancreatic Cancer

Prognostic Impact of Lymphocyte-to-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Pancreatic Cancer

C-Reactive Protein as Predictive Biomarker for Response to Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Retrospective Study

Prognostic value of lymphocyte-to-C-reactive-protein ratio in cancers

Contact Info

Product

Resources

About